Summit Corporation plc
('Summit' or 'the Company')
APPOINTMENT OF NOMINATED ADVISER
Oxford, UK, 26 September 2013 - Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infection, is pleased to announce the appointment with immediate effect of Cairn Financial Advisers as the Company's Nominated Adviser (Nomad).
- END -
Notes to Editors
About Summit
Summit is an Oxford, UK based drug discovery and development Company targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection. Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com and follow Summit on Twitter (@summitplc).
For more information, please contact:
| Summit Glyn Edwards / Richard Pye | Tel: +44 (0)1235 443 951 +44 (0)7825 313 476 |
| Cairn Financial Advisers (Nominated Adviser) Tony Rawlinson / Liam Murray | Tel: +44 (0)20 7148 7900 |
| Hybridan LLP (Broker) Claire Louise Noyce / William Lynne | Tel: +44 (0)207 947 4350 / 4361 |
| Peckwater PR (Financial public relations, UK) Tarquin Edwards | Tel: +44 (0)7879 458 364 tarquin.edwards@peckwaterpr.co.uk |
| MacDougall Biomedical Communications (US media contact) Michelle Avery | Tel: +1 781-235-3060 |